Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.
A wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., Sunovion was formed following the merger of Sumitomo Dainippon Pharma's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the life-affirming energy of the sun and the power of innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.
|4/27/16||Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow® (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)|
|4/15/16||Sunovion Announces Results of Health Outcomes Analyses Supporting the Use of Aptiom® (eslicarbazepine acetate) in People with Partial-Onset Seizures at the 68th American Academy of Neurology (AAN) Annual Meeting|
|4/6/16||Sunovion to Present Data Analyses Supporting Use of Aptiom® (eslicarbazepine acetate) at the 68th American Academy of Neurology (AAN) Annual Meeting|
|3/7/16||New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients|
|1/25/16||Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline|